14294-10-1

Usage

Chemical Properties

White to off-white solid

InChI:InChI=1/C5H10N2OS/c6-5(9)7-1-3-8-4-2-7/h1-4H2,(H2,6,9)

Upstream product

• 110-91-8 morpholine 
• 625-57-0 O-ethyl thiocarbamate 
• 1530-89-8 N-cyanomorpholine 
• 55113-93-4 morpholine-4-carbothioic acid 1,1-dimethyl-3-oxo-butylamide 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 314278-55-2 benzotriazol-1-yl(tetrahydro-1H-1,4-oxazin-4-yl)methanimine 
• 540-72-7 sodium thiocyanide 
• 109-02-4 4-methyl-morpholine 
• 2290-65-5 trimethylsilyl isothiocyanate 
• 40398-30-9 N-(morpholinothiocarbonyl)benzamide 
• 1094484-89-5 2-mercapto-2-morpholin-4-yl-2,3,5,6,7,8-hexahydro-4H-1,3-benzoxazin-4-one 
• 862873-20-9 4-(1H-imidazol-1-ylcarbonothioyl)morpholine 
• 288-32-4 1H-imidazole 
• 75-15-0 carbon disulfide 

Downstream Products

• 70757-27-6 2-morpholin-4-yl-4-phenyl-[1,3]thiazine-6-thione 
• 83241-50-3 Morpholine-4-carboximidothioic acid (Z)-3-oxo-3-phenyl-propenyl ester; compound with perchloric acid 
• 118200-06-9 2-Morpholin-4-yl-4-p-tolyl-[1,3]thiazine-6-thione 
• 118200-08-1 4-(4-Chloro-phenyl)-2-morpholin-4-yl-[1,3]thiazine-6-thione 
• 118200-10-5 4-(4-Bromo-phenyl)-2-morpholin-4-yl-[1,3]thiazine-6-thione 
• 83241-52-5 Morpholine-4-carboximidothioic acid (Z)-3-oxo-3-p-tolyl-propenyl ester; compound with perchloric acid 
• 83241-54-7 Morpholine-4-carboximidothioic acid (Z)-3-(4-methoxy-phenyl)-3-oxo-propenyl ester; compound with perchloric acid 
• 83241-56-9 Morpholine-4-carboximidothioic acid (Z)-3-(4-chloro-phenyl)-3-oxo-propenyl ester; compound with perchloric acid 
• 83241-58-1 Morpholine-4-carboximidothioic acid (Z)-3-(4-bromo-phenyl)-3-oxo-propenyl ester; compound with perchloric acid 
• 80733-27-3 3-Thiobenzoyl-morpholino-thioharnstoff 
• 19983-28-9 (4-(4-phenylthiazol-2-yl)morpholine) 
• 209049-98-9 2-morpholino-4-phenyl-5[2-(4-morpholino)-4-thiazolyl]thiazole 
• 860344-51-0 4-(2-morpholin-4-yl-thiazol-4-yl)-benzoic acid 
• 196810-40-9 (S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-morpholin-4-yl-thiazol-4-yl)-ethoxy]-phenyl}-propionic acid methyl ester 

Relevant academic research and scientific papers

Pyrrole-thiazole based push-pull chromophores: An experimental and theoretical approach to structural, spectroscopic and NLO properties of the novel styryl dyes

Novel push-pull fluorophores constituted by two donors (substituted pyrrole and morpholine) linked to acceptor through thiazole electron spacer have been synthesized. The fluorophores are investigated for linear and non-linear optical properties by UV-VIS absorption and fluorescence spectroscopies, and by means of TD-DFT (B3LYP/6-31G(d)) method, with the aim of elucidating the ability of the morpholine/pyrrole-donor-thiazole-spacer based D-π-A fluorophores as organic NLO materials. The bond length alternation and generalized Mulliken-Hush (GMH) analysis is performed to understand the involvement of the donor in effective transfer of the charge to acceptor. Values of first-order hyperpolarizabilities (βCT or β0), obtained by the solvatochromic method (Lippert Mataga model), and the transition dipole moments (μeg) used to characterize and evaluate the non-linear optical performances of the D-π-A fluorophores in various microenvironments. The D-π-A fluorophores possess good values of βCT or β0 in different organic solvents and hold high thermal stabilities therefore can be used as potential organic NLO materials.

Resonance induced proton transfer leading to NIR emission in coumarin thiazole hybrid dyes: Synthesis and DFT insights

Two novel coumarin thiazole hybrid dyes (E)-2-(3-(2-(4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2-morpholinothiazol-5-yl)vinyl)-5,5-dimethylcyclohex-2-en-1-ylidene)malononitrile (CSI) and (E)-2-(3-(2-(4-(4-methoxy-2-oxo-2H-chromen-3-yl)-2-morpholinothiazol-5-yl)vinyl)-5,5-dimethylcyclohex-2-en-1-ylidene)malononitrile (MeOCSI) were synthesized. CSI exhibits near infrared emission with very large Stokes shift. The dye CSI shows resonance induced excited state intramolecular proton transfer (RI-ESIPT). DFT and TD-DFT calculations clearly support and define the finding.

Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis

8-Nitrobenzothiazinones (BTZs) are a promising class of antimycobacterial agents currently under investigation in clinical trials. Starting from thiourea derivatives, a new synthetic pathway to BTZs was established. It allows the formation of the thiazinone ring system in one synthetic step and is applicable for preparation of a wide variety of BTZ analogues. The synthetic procedure furthermore facilitates the replacement of the sulphur atom in the thiazinone ring system by oxygen or nitrogen to afford the analogous benzoxazinone and quinazolinone systems. 36 BTZ analogues were prepared and tested in luminescence-based assays for in vitro activity against Mycobacterium tuberculosis (Mtb) using the microdilution broth method and a high-throughput macrophage infection assay.

Imidazo ring PAR4 antagonist and medical applications thereof

The invention relates to an imidazo ring compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt or ester or solvate thereof. The compound disclosed by the inventioncan be used for preparing medicines for preventing or treating thromboembolic diseases.

Agonists for the adenosine A1 receptor with tunable residence time. a case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines

We report the synthesis and evaluation of previously unreported 4-amino-6-aryl-5-cyano-2-thiopyrimidines as selective human adenosine A 1 receptor (hA1AR) agonists with tunable binding kinetics, this without affecting their nanomolar affinity for the target receptor. They show a very diverse range of kinetic profiles (from 1 min (compound 52) to 1 h (compound 43)), and their structure-affinity relationships (SAR) and structure-kinetics relationships (SKR) were established. When put in perspective with the increasing importance of binding kinetics in drug discovery, these results bring new evidence of the consequences of affinity-only driven selection of drug candidates, that is, the potential elimination of slightly less active compounds that may display preferable binding kinetics.

Synthesis and characterization of novel yellow azo dyes from 2-morpholin-4-yl-1,3-thiazol-4(5H)-one and study of their azo-hydrazone tautomerism

Novel yellow azo dyes were synthesized by diazotization of aromatic amines followed by coupling with 2-morpholin-4-yl-1,3-thiazol-4(5H)-one and fully characterized. The geometries of the synthesized dyes for azo and hydrazone tautomeric forms were optimized using B3LYP, CAM-B3LYP and M06 functional and 6-31G(d) and 6-311++G (d,p) basis sets, also their electronic excitation properties were evaluated using density functional theory. The optimized geometries reveal that the hydrazone for is more stable than the azo form. Photophysical properties of the synthesized dyes were evaluated by UV-Visible spectroscopy and compared with computed vertical excitation obtained from TDDFT. The results clearly illustrate existence of dye 8a, 8b and 8c in hydrazone tautomeric form, while 8d exist in both azo as well as hydrazone form. Thermal stabilities were estimated by using thermo gravimetric analysis, and results revels that the synthesized dyes have good thermal stability.

IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Reaction of Ph3P(SCN)2 with further orthohydroxy carboxylic acid systems, including substituted β-keto acids: Synthesis of novel 2-thio-1,3-oxazines and their subsequent transformation with amines

We now report the first reaction of Ph3P(SCN)2 with 4,6-dihydroxy-5- methylisophthalic acid to give 10-methyl-2,8-dithio-1,3-oxazino-1,3-benzoxazine- 4,6-dione. Also, the enol tautomer has been utilized in the reaction of β-keto acids with Ph3P(SCN)2 to give novel 2-thio-1,3-oxazines. Subsequent reaction of the 2-thio-1,3-oxazines with benzylamine resulted in opening of the oxazine ring and gave novel dibenzylamino-enamides, which could be cyclized to thiouracils. The reaction of 2-thio-1,3-oxazines with morpholine at low temperature led to the production of unstable 2-Mercapto-2-morpholino-1,3- oxazines. 2-Mercapto-2-morpholin-4-yl-2,3,5,6,7,8-hexahydro-4H-1,3-benzoxazin-4- one was observed to lose H2S at room temperature to give 2-morpholin-4-yl-5,6,7, 8-tetrahydro-4H-1,3-benzoxazin-4-one, which was subsequently tested and found to exhibit some antiplatelet activity. Copyright Taylor & Francis Group, LLC.

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 5,6-dihydro-l,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of b.enefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

THIAZOLE DERIVATIVES AND USE THEREOF

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.